All In Biotech

NDA 210308 · Sun Pharm

Yonsa

Abiraterone Acetate · Oral

Last checked: Nov 19, 2026Latest source record: May 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

May 22, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

415

71 Phase 3, 75 recruiting

FAERS reports

6,863

5,670 serious, 1,274 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 6, 2026.

YONSA is indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer. YONSA is a CYP17 inhibitor indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 )

Mechanism: Abiraterone acetate (YONSA) is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. CYP17 catalyzes two sequential reactions: 1) the conversion of pregnenolone and progesterone to their 17α-hydroxy derivatives by 17α-hydroxylase activity and 2) the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by C17,20-lyase activity. DHEA and androstenedione are androgens and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 22, 2018 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • YONSA · ABIRATERONE ACETATE 125MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Abiraterone" as an intervention, any sponsor and status, largest first.

All 415 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death751
  • fatigue513
  • hot flush294
  • asthenia279
  • anaemia247
  • hypokalaemia240
  • diarrhoea217
  • prostatic specific antigen increased217
  • disease progression215
  • drug ineffective213
  • prostate cancer210
  • pneumonia208

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201013
2011119
2012213
2013123
2014214
2015199
2016161
2017203
2018267
2019514
2020728
2021541
2022788
2023834
2024579
2025852
2026515

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Yonsa (Abiraterone Acet,Submicronized)

2024 spending

$15.5M

Beneficiaries

230

1,538 claims

Per beneficiary

$67,281

$83.59 per unit

View as table
YearSpending
2020$15,672,149
2021$14,971,581
2022$13,940,088
2023$14,025,107
2024$15,474,644

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 603 on PubMed

Sponsor: Sun Pharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.